Current Meeting     Our Mission     Future & Past Programs      Sponsorship     Board of Directors     Contact Us
Meeting Announcement
Register  Map
Date: Wednesday, May 27th, 2015
Topic: "First in Human Experience with a Novel Inhibitor of Fatty Acid Synthase for the Treatment of Solid Tumors"
Speaker: Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
3-V Biosciences
Location:

The Holiday Inn
275 S Airport Blvd
South San Francisco, CA 94080
650-873-3550 | Map
Next door to the SSF Conference Center
Directions at www.hisfo.com

Price:

$50 before 9PM, Monday, May 25th
$60 on-site
$40 full-time students pre-registration
$50 full-time students on-site
$3 service fees will be added to the pre-registration prices

6:00 PM - networking
7:00 PM - dinner
8:00 PM - presentation

Abstract:

Lipids play a vital role in both cellular signaling and metabolism. Recent advances in technology have allowed the study of their role in cancer, viral infections and other disease processes. A critical fatty acid, palmitate, is generated by the enzyme fatty acid synthase (FASN). Palmitate is a central regulator in multiple pathways and a key precursor to many important cellular building blocks. Dysregulation of palmitate is critical to the pathology of cancer and viral infections.

Targeting FASN for oncology has a strong rationale based on its key role in lipid metabolism, lipid signaling and tumor cell survival. TVB-2640, is an oral, potent, specific, reversible inhibitor of FASN. Inhibiting FASN reduces the synthesis of palmitate, resulting in changes to lipid rafts, and alterations in the signaling through receptor tyrosine kinases, and palmitate-modified proteins such as Wnt. It also inhibits the ability of tumor cells to use palmitate as an energy source. These effects lead to anti-tumor effects demonstrated in cell lines, in cell-line based xenograft studies, and in patient-derived tumor xenograft studies. 3-V Biosciences has initiated a first-in-human Phase 1 clinical study with TVB-2640 in patients with advanced solid tumors based on the demonstrated activity of FASN inhibition in multiple tumor types in preclinical studies. In the ongoing study, TVB-2640 has demonstrated good exposure, tolerability and early signs of clinical benefit supporting continued development and advancement to expansion cohorts.

The role of lipid biology in viral replication is also being targeted as a therapeutic approach. FASN exploits the dependency of viruses on host pathways for replication, resulting in a new class of antiviral agents designed to have broad-spectrum antiviral activity and high barrier to resistance.

Biography:

Dr. Parsey joined 3-V Biosciences as its Chief Executive Officer in 2010. Prior to joining 3-V, Dr. Parsey held positions of increasing responsibilities at Genentech, Inc., Sepracor, Regeneron and Merck, Inc. He was also the Director of Critical Care Medicine at the NYU School of Medicine.

Dr. Parsey completed his MD and PhD at the University of Maryland, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

Registration Policy    Registration via CEvent

Platinum Sponsors

Novartis
Pii

Gold Sponsors

Patheon
PPS
ChanTest
ReImagine Science
Deloitte
RHS Financial
MSL Group
SomaLogic
Pharmatek

Silver Sponsors

WAVSIP
Formurex
PerkinElmer
© BioSF.org ALL RIGHTS RESERVED BioScience Forum